[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 2007

Biomarkers in Dementia

Arch Neurol. 2007;64(9):1356. doi:10.1001/archneur.64.9.1356

Fagan et al1 followed up a group of 61 normal elderly individuals (Clinical Dementia Rating [CDR] 0, ≥60 years old) for a mean time of 3 to 4 years to study cognitive decline. Individuals who progressed during the follow-up from a CDR of 0 to a CDR of 0.5 or higher were defined as converters toward very mild or mild dementia. All the other subjects were considered nonconverters. A cutoff value of 0.214 or greater for the ratio of cerebrospinal fluid (CSF) phosphorylated tau181/β-amyloid42 (ptau181/Aβ42) at baseline was adopted to predict converters and nonconverters at follow-up. The authors' conclusion is that, “CSF tau/Aβ42 ratios show strong promise as antecedent (preclinical) biomarkers that predict future dementia in cognitively normal older adults.”

First Page Preview View Large
First page PDF preview
First page PDF preview